These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 6420165)

  • 1. Pharmacokinetics of tocainide in patients with combined hepatic and renal dysfunction.
    Oltmanns D; Pottage A; Endell W
    Eur J Clin Pharmacol; 1983; 25(6):787-90. PubMed ID: 6420165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis.
    Wiegers U; Hanrath P; Kuck KH; Pottage A; Graffner C; Augustin J; Runge M
    Eur J Clin Pharmacol; 1983; 24(4):503-7. PubMed ID: 6407848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of tocainide in patients with severe renal failure.
    Braun J; Sörgel F; Engelmaier F; Gluth WP; Gessler U
    Eur J Clin Pharmacol; 1985; 28(6):665-70. PubMed ID: 3933983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereoselective pharmacokinetics of tocainide in human uraemic patients and in healthy subjects.
    McErlane KM; Axelson J; Vaughan R; Kerr CR; Price JD; Igwemezie L; Pillai G
    Eur J Clin Pharmacol; 1990; 39(4):373-6. PubMed ID: 2127569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteration of the kinetics of tocainide in combined hepatic and renal insufficiency.
    Endell W; Oltmanns D; Pottage T
    Methods Find Exp Clin Pharmacol; 1983 Oct; 5(8):589-90. PubMed ID: 6420626
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetics and haemodynamic effects of tocainide in patients with acute myocardial infarction complicated by left ventricular failure.
    MacMahon B; Bakshi M; Branagan P; Kelly JG; Walsh MJ
    Br J Clin Pharmacol; 1985 Apr; 19(4):429-34. PubMed ID: 3922392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereoselective disposition of RS-tocainide in man.
    Hoffmann KJ; Renberg L; Bäärnhielm C
    Eur J Drug Metab Pharmacokinet; 1984; 9(3):215-22. PubMed ID: 6440790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The appropriate dosage regime for the transition from intravenous lignocaine to oral tocainide after acute myocardial infarction.
    Upward JW; Holt D; Emery P; Akhras F; Jackson G
    Eur J Clin Pharmacol; 1983; 25(5):589-94. PubMed ID: 6420162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereospecific salivary excretion of tocainide enantiomers in man.
    Pillai GK; Axelson JE; Kerr CR; McErlane KM
    Res Commun Chem Pathol Pharmacol; 1984 Feb; 43(2):209-21. PubMed ID: 6424192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the kinetics and dynamics of tocainide and its metabolites.
    Ronfeld RA; Wolshin EM; Block AJ
    Clin Pharmacol Ther; 1982 Mar; 31(3):384-92. PubMed ID: 6800678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis and stereoselective metabolism after separate oral doses of tocainide enantiomers to healthy volunteers.
    Hoffmann KJ; Renberg L; Gyllenhaal O
    Biopharm Drug Dispos; 1990; 11(4):351-63. PubMed ID: 2111189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocainide. A review of its pharmacological properties and therapeutic efficacy.
    Holmes B; Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1983 Aug; 26(2):93-123. PubMed ID: 6411445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of the newer antiarrhythmic agents.
    Gillis AM; Kates RE
    Clin Pharmacokinet; 1984; 9(5):375-403. PubMed ID: 6437721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocainide kinetics in congestive heart failure.
    Mohiuddin SM; Esterbrooks D; Hilleman DE; Aronow WS; Patterson AJ; Sketch MH; Mooss AN; Hee TT; Reich JW
    Clin Pharmacol Ther; 1983 Nov; 34(5):596-603. PubMed ID: 6414753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic principles of lidocaine dosing in relation to disease state.
    Waller ES
    J Clin Pharmacol; 1981 Apr; 21(4):181-94. PubMed ID: 7240439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of the oral antiarrhythmic lidocaine congener, tocainide.
    Lalka D; Meyer MB; Duce BR; Elvin AT
    Clin Pharmacol Ther; 1976 Jun; 19(6):757-66. PubMed ID: 1269216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetics of R- and S-tocainide in patients with acute ventricular arrhythmias.
    Thomson AH; Murdoch G; Pottage A; Kelman AW; Whiting B; Hillis WS
    Br J Clin Pharmacol; 1986 Feb; 21(2):149-54. PubMed ID: 3082345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of rifampin on tocainide pharmacokinetics in humans.
    Rice TL; Patterson JH; Celestin C; Foster JR; Powell JR
    Clin Pharm; 1989 Mar; 8(3):200-5. PubMed ID: 2495879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents.
    Woosley RL; Echt DS; Roden DM
    Am J Cardiol; 1986 Jan; 57(3):25B-33B. PubMed ID: 3080860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.